The confusion about Ozempic vs Wegovy is completely understandable — they are literally the same molecule (semaglutide), made by the same company (Novo Nordisk), administered the same way (subcutaneous injection once weekly), and share the same GLP-1 receptor agonist mechanism of action. The difference is in FDA indication, maximum approved dose, and pen device. This distinction exists for regulatory, clinical trial, and insurance/reimbursement reasons — not because the two products are pharmacologically distinct.
Understanding this distinction matters practically: it determines which drug your physician can prescribe for your specific diagnosis, which one your insurance will cover (and at what cost-sharing), whether "off-label" use becomes relevant, and what to expect from compounded semaglutide alternatives when supply constraints make branded products unavailable.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (identical) |
| Manufacturer | Novo Nordisk | Novo Nordisk (identical) |
| FDA approval | Dec 2017: T2D glycemic control; March 2020: cardiovascular risk reduction in T2D with CVD | June 2021: chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidity) |
| Maximum approved dose | 2mg/week | 2.4mg/week |
| Dose escalation steps | 0.25mg × 4 weeks → 0.5mg × 4 weeks → 1mg (maintenance); can increase to 2mg if additional glycemic control needed | 0.25mg × 4 weeks → 0.5mg × 4 weeks → 1mg × 4 weeks → 1.7mg × 4 weeks → 2.4mg (maintenance); full escalation takes ~5 months |
| Pen device | Multi-dose FlexTouch pen (4 doses per pen) | Single-dose pen (1 injection per pen) |
| List price (US, mid-2026) | ~$935/month (2mg) | ~$1,349/month (2.4mg) |
| Insurance coverage | Typically covered for T2D with formulary prior authorization; most Part D plans cover | Coverage for obesity improving post-SELECT; some plans still exclude obesity drugs; Medicare Part D excluded by law until 2026 legislation change |
| Mean weight loss in pivotal trial | ~6–7% from SUSTAIN trials (diabetic population, glycemic control endpoint); weight loss is secondary | 14.9% from STEP 1 (non-diabetic, weight loss endpoint); higher because weight loss is primary endpoint and dose is higher |
| CV outcomes data | SUSTAIN-6 (2016, N=3,297 T2D): 26% reduction in MACE; SOUL trial (2024, oral semaglutide) | SELECT trial (2023, N=17,604 non-diabetic with CVD): 20% reduction in MACE — landmark non-diabetic CV evidence |
| Off-label use | Commonly prescribed off-label for weight loss (same drug as Wegovy, but max 2mg vs 2.4mg) | Not meaningfully prescribed off-label since it IS the weight loss indication |
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults with established cardiovascular disease (prior MI, stroke, or peripheral arterial disease) who were overweight or obese (BMI ≥27) but did NOT have diabetes. This was a critical distinction — previous GLP-1 cardiovascular trials (LEADER, SUSTAIN-6, PIONEER 6) were all in diabetic populations. SELECT asked whether semaglutide's cardiovascular benefit is solely due to glycemic control, or whether there is a separate mechanism in non-diabetic people with obesity. The answer was unambiguous: 20% reduction in the composite of CV death, non-fatal MI, and non-fatal stroke (6.5% vs 8.0%, HR 0.80, p<0.001) over 34 months of follow-up. This finding has direct implications for Wegovy prescribing: the FDA expanded Wegovy's label in March 2024 to include reduction of cardiovascular events in adults with established CVD and obesity/overweight, making Wegovy a cardiovascular drug, not just an obesity drug — with direct insurance reimbursement implications.
If you have type 2 diabetes: Ozempic is the appropriate first-line choice — it is FDA-approved for T2D, most likely covered by your insurance, and your endocrinologist or PCP will prescribe it on-label. Ozempic's max dose (2mg) achieves significant A1c reduction and meaningful weight loss (6–7%). If weight loss beyond what Ozempic provides is needed, some physicians will prescribe Wegovy in addition to or instead of Ozempic — the same molecule at higher dose — but this requires documentation of the obesity indication.
If you have obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity WITHOUT diabetes: Wegovy is the appropriate on-label choice — FDA-approved for your indication, and with SELECT trial data, increasingly covered by commercial insurance for patients with established CVD. Without CVD, you may face more insurance battles; document BMI, comorbidities (hypertension, sleep apnea, dyslipidemia), and prior weight loss attempts.
Off-label Ozempic for weight loss: Many physicians prescribe Ozempic off-label for obesity, particularly when Wegovy supply is constrained or when insurance covers Ozempic (T2D indication) but not Wegovy (obesity indication) — even in patients without diabetes. This is legal and common; the drug is identical; the maximum dose achievable is 2mg rather than 2.4mg. The 0.4mg dose difference at max produces roughly 2–3% less weight loss on average — meaningful but not dramatic.
Compounded semaglutide: During the shortage periods (2022–2024), FDA allowed 503B compounding pharmacies to produce semaglutide. As of 2026, Novo Nordisk has largely resolved supply, and FDA has determined that Ozempic and Wegovy are not in shortage — making compounded semaglutide production for these specific drugs legally prohibited (FDA Final Rule, October 2024). Compounded semaglutide from offshore pharmacies or unapproved sources carries serious safety risks (incorrect dosing, contamination, no pharmacovigilance) and is not recommended.
Getting coverage approved: For Wegovy with commercial insurance: (1) document BMI ≥30 or ≥27 with comorbidities; (2) document 3–6 months of lifestyle intervention attempts; (3) submit prior authorization with ICD-10 code E66.01 (morbid obesity) and comorbidity codes; (4) if denied, appeal citing SELECT trial CV outcomes data for patients with CVD; (5) if still denied, check manufacturer savings programs (Novo Nordisk Wegovy Savings Card: ~$0 copay for eligible commercially-insured patients up to $500/month savings). For Medicare: obesity drug coverage changes took effect January 2026 for qualifying patients with CVD per the Inflation Reduction Act amendments.